Počet záznamov: 1
imatinib mezylát
SYS d000068877 LBL 00000nz--a2200181n--4500 005 20250606221740.2 008 160101|||anznnbabn-----------|-a|a------ 040 $b slo $a BA006 $d BA006 065 $a D02.065.277.456 065 $a D02.241.223.100.100.435 065 $a D02.455.426.559.389.127.085.465 065 $a D03.383.606.405 065 $a D03.383.742.349 066 $a 01 $c 03 150 $a imatinib mezylát $x AA $x AD $x AE $x AG $x AI $x AN $x BL $x CF $x CH $x CL $x CS $x EC $x HI $x IM $x IP $x ME $x PD $x PK $x PO $x RE $x SD $x ST $x TO $x TU $x UR $2 slo 450 $w v $a CGP 57148 $2 slo 450 $w v $a imatinib $2 slo 450 $w v $a imatinib metánsulfonát $2 slo 450 $w v $a ST 1571 $2 slo 550 $7 sllk_us_auth*d000970 $Y Antineoplastic Agents $w P $a antineoplastiká 550 $7 sllk_us_auth*d000092004 $Y Tyrosine Kinase Inhibitors $w P $a inhibítory tyrozínkináz 665 $a 2016 (1996) $2 eng 680 9-
$i A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors. $2 eng 750 -2
$a Imatinib Mesylate $2 eng 980 $x M
Počet záznamov: 1